Aptamers, nucleic acids capable of selectively binding to viruses, proteins, ions, small molecules, and various other targets, are garnering attention in drug development as potential antibody substitutes for their thermal and chemical stability as well as ability to inhibit specific enzymes or target proteins through three-dimensional binding. They also hold promise for swift diagnoses of colon cancer and other challenging diseases by targeting elusive biomarkers. Despite their utility, these aptamers are susceptible to easy degradation by multiple enzymes, presenting a significant challenge.